Skip to main content
Smart Investors Daily
AstraZeneca PLC logo

NASDAQ · AZN

AstraZeneca PLC

Healthcare · Drug Manufacturers - General

$174.35

Down-$1.06 (-0.60%)

Updated Nov 22, 2026, 1:14 PM

SID Score

7.4/10

Composite research score

Smart Money

58/100

Neutral

Market cap
279.95B
P/E ratio
33.06
Dividend yield
0.88%
52-week range
$88.41 – $212.71
Volume
2.02M
Avg. volume
5.47M

Price performance · AZN

AZN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 20, 2026

AZN closed at $174.35 after 20 trading sessions, up 1.33% for the selected period.

Last close
$174.35
Period change
+1.33%
Period low
$169.51
Period high
$189.39
Daily close
View OHLC price history
AZN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 20, 2026$176.14$177.47$174.04$174.352.02M
Nov 19, 2026$177.10$178.29$174.03$175.412.58M
Nov 18, 2026$180.005$181.50$178.29$178.762.54M
Nov 17, 2026$181.25$183.66$181.08$182.272.37M
Nov 16, 2026$186.905$187.685$183.86$184.021.95M
Nov 13, 2026$184.77$186.145$183.93$184.451.85M
Nov 12, 2026$185.47$185.845$183.87$184.381.71M
Nov 11, 2026$184.26$185.71$183.53$185.481.43M
Nov 10, 2026$186.71$188.10$184.96$186.761.8M
Nov 9, 2026$189.36$190.1651$187.21$189.392.43M
Nov 6, 2026$181.34$187.33$181.2035$186.432.85M
Nov 5, 2026$190.00$192.645$186.48$186.854.84M
Nov 4, 2026$188.44$189.66$187.11$189.014.56M
Nov 3, 2026$186.11$187.355$182.93$183.883.89M
Nov 2, 2026$184.59$187.94$184.52$186.582.7M
Oct 30, 2026$183.59$188.39$183.10$186.655.47M
Oct 29, 2026$173.26$175.35$172.87$174.403.72M
Oct 28, 2026$168.645$171.94$167.96$169.511.7M
Oct 27, 2026$169.68$171.72$169.4501$170.082.91M
Oct 26, 2026$171.54$172.37$170.675$172.063.31M

Latest AZN news

The latest Smart Investors Daily articles mentioning AZN.

AZN research

Overview

Company profile and research snapshot.

Company profile

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$102.67
Implied upside
—
Analysts
6
AZN recent ratings
DateFirmRatingTarget
Jul 13, 2026Berenberg BankBuy—
Jun 26, 2026DeutscheSell—
Jun 26, 2026JefferiesBuy—
Jun 11, 2026DeutscheSell—
Jun 9, 2026JefferiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 21, 2026

3 British Stocks Trading Up To 43% Below Cash Flow Value

With the Nasdaq sliding into correction territory after an AI driven selloff, many popular momentum stocks now look far less certain. That kind of shakeout often leaves quieter cash generators in the shadows, even when their future cash flows look attractive relative to current prices. This piece highlights three United Kingdom listed businesses that our cash flow screen currently flags as trading below estimated fair value based on discounted cash flow analysis. The three stocks highlighted...

Yahoo · Nov 20, 2026

European shares tumble again as Anthropic debut fails to halt tech rout

Investing.com - European equities posted a brutal end to the trading week on Friday, sinking to a month-long low and heading to their worst weekly performance since March 2025, as the market debut of artificial intelligence-bellwether Anthropic failed to reignite global tech sentiment.

Yahoo · Nov 19, 2026

Why AstraZeneca Could Make Sense Through ETFs Now

Owning AstraZeneca directly means your results lean heavily on what happens to that single business. Simply Wall St highlights that the group has a high level of debt, and that late stage research such as the large transthyretin cardiomyopathy trial for Wainua can still fall short. Holding AstraZeneca through a fund that also owns many other companies can dilute how much those specific risks sway your portfolio, and it also tempers any potential upside if things go well. The fresh twist is a...

AI research layers

Interpretive context generated from the platform’s current data sources.

AstraZeneca PLC Stock Performance

AstraZeneca PLC has demonstrated strong momentum across multiple timeframes, with shares trading at $178.76. Per SID market data, AZN has gained 11.17% over the past month and 10.5% over the trailing three months, while the one-year return stands at an impressive 105.7%. The stock currently trades above its 50-day moving average of $169.68, reflecting sustained near-term bullish momentum, though it remains slightly below the 200-day moving average of $180.12. The 14-day relative strength index reads 66.9, indicating the stock is approaching overbought territory but has not yet crossed the conventional threshold. AZN's beta of 0.168, according to Massive/Polygon data, underscores its notably low correlation with broader market movements, characteristic of large-cap pharmaceutical names. Average daily trading volume stands at approximately 5.47 million shares, supporting consistent liquidity for institutional participants navigating this $279.9 billion market capitalization security.

AstraZeneca PLC Valuation Analysis

AstraZeneca PLC trades at a price-to-earnings ratio of 33.06, representing a premium valuation relative to the broader Healthcare sector, per SID market data. The PEG ratio stands at 4.53, suggesting the current earnings multiple substantially exceeds the company's projected growth rate, which may reflect the market pricing in long-term pipeline optionality. The price-to-book ratio of 6.24 further indicates investors are assigning significant value to intangible assets, including AstraZeneca's oncology and rare disease portfolios. According to SEC filings, the company offers a dividend yield of approximately 1.56%, providing a modest income component for shareholders. With a market capitalization of approximately $279.9 billion, AZN ranks among the largest global pharmaceutical companies. These valuation metrics collectively position AstraZeneca at a growth-oriented premium, reflecting elevated investor expectations for sustained revenue expansion from its diversified therapeutic pipeline and recent commercial successes.

Smart Money Activity for AZN

AstraZeneca PLC registers a smart money score of 59, reflecting a neutral composite signal across key institutional and insider tracking metrics. According to 13F institutional filings, AZN receives a perfect institutional score of 25 out of 25, indicating robust accumulation and sustained positioning by major fund managers. In contrast, the dark pool activity score sits at just 9.0 out of 25, suggesting limited off-exchange block trading activity in recent periods. Per SEC Form 4 filings, three insider transactions have been recorded over the past 90 days, all of which were purchases with zero insider sales, yielding an insider score of 12.5 out of 25. This unanimously bullish insider buying pattern signals internal confidence in the company's forward trajectory. The congressional trading score stands at 12 out of 25, indicating moderate legislative interest. The divergence between strong institutional accumulation and subdued dark pool activity creates a mixed but cautiously constructive smart money profile for AZN, warranting continued monitoring of insider transaction patterns.

AstraZeneca PLC Earnings Outlook

AstraZeneca PLC has delivered substantial earnings surprises in its most recent reported quarters, according to company earnings reports. In the latest reported period, AZN posted actual earnings per share of $2.79 against an analyst estimate of $1.44, representing a positive surprise of $1.35, or approximately 93.8%. The prior reported quarter showed similarly robust outperformance, with actual EPS of $2.63 versus the consensus estimate of $1.52, yielding a $1.11 positive surprise. These consecutive beats underscore the company's ability to exceed market expectations through accelerating revenue growth and operational leverage. Looking ahead, per analyst estimates, the upcoming quarter carries a consensus EPS estimate of $1.44, with a subsequent quarter estimate of $1.35. AstraZeneca's next earnings report is scheduled for July 28, 2026. The pattern of meaningful upside surprises positions AZN favorably heading into its forthcoming reporting cycle.

Wall Street Analyst Ratings for AZN

Wall Street analyst coverage of AstraZeneca PLC reflects a divided outlook, per SID consensus data and recent analyst reports. On July 13, 2026, Berenberg Bank reiterated a Buy rating on AZN, reinforcing its constructive thesis on the company's commercial and pipeline trajectory. Jefferies has also maintained a Buy rating, reiterating on both June 26 and June 9, 2026, signaling sustained conviction in AstraZeneca's growth profile. In contrast, Deutsche Bank has taken a bearish stance, reiterating a Sell rating on June 26 and June 11, 2026, representing the notable dissenting view among recent coverage updates. This creates a clear bifurcation among analysts, with two firms maintaining Buy ratings and one firm holding a Sell recommendation across the five most recent rating actions. The divergence highlights differing assessments of AstraZeneca's valuation sustainability at its current P/E of 33.06 relative to pipeline execution risks and competitive dynamics within the global pharmaceutical landscape.